keyword
https://read.qxmd.com/read/38537212/complete-resolution-of-locally-advanced-prostate-cancer-after-molecular-endoradiotherapy-with-177lu-psma
#1
JOURNAL ARTICLE
Mohsen Beheshti, Reza Vali, Soroush Zarehparvar Moghadam, HamidReza Amini, Masoumeh Hakiminejad, GhasemAli Divband
A 76-year-old man with castration-resistant prostate cancer underwent 68Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177Lu-PSMA were administered, and the patient showed significant reduction of hematuria as well as declining in PSA levels. 177Lu-PSMA therapy can be a good treatment option in patients with locally invasive tumors.
March 25, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38536119/m6a-modification-promotes-emt-and-metastasis-of-castration-resistant-prostate-cancer-by-upregulating-nfib
#2
JOURNAL ARTICLE
Feng Shu, Hao Liu, Xiaohui Chen, Ye Liu, Jiangli Zhou, Lei Tang, Wanwei Cao, Shanshan Yang, Yili Long, Rongna Li, Hao Wang, Hongsheng Wang, Guanmin Jiang
The widespread use of androgen receptor (AR) signaling inhibitors has led to an increased incidence of AR-negative castration-resistant prostate cancer (CRPC), limiting effective treatment and patient survival. A more comprehensive understanding of the molecular mechanisms supporting AR-negative CRPC could reveal therapeutic vulnerabilities to improve treatment. This study showed that the transcription factor nuclear factor I/B (NFIB) was upregulated in AR-negative CRPC patient tumors and cell lines and was positively associated with an epithelial-to-mesenchymal transition (EMT) phenotype...
March 27, 2024: Cancer Research
https://read.qxmd.com/read/38536082/a-phase-i-trial-of-enzalutamide-plus-selective-glucocorticoid-receptor-modulator-relacorilant-in-patients-with-metastatic-castration-resistant-prostate-cancer
#3
JOURNAL ARTICLE
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Z Szmulewitz
PURPOSE: Majority of patients with metastatic prostate cancer who receive androgen deprivation therapy and androgen receptor (AR) signaling inhibitors progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI-resistance. This single-arm phase I trial assessed safety and pharmacokinetic feasibility of combined AR antagonist (enzalutamide) and selective GR modulator (relacorilant) in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: This was a phase I trial (NCT03674814) of relacorilant and enzalutamide in refractory mCRPC patients enrolled using 6+3 design...
March 27, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38535843/characterization-of-the-pro-inflammatory-and-pruritogenic-transcriptome-in-skin-lesions-of-the-experimental-canine-atopic-acute-ige-mediated-late-phase-reactions-model-and-correlation-to-acute-skin-lesions-of-human-atopic-dermatitis
#4
JOURNAL ARTICLE
Amanda Blubaugh, Kathleen Hoover, Sujung Jun Kim, Jonathan E Fogle, Fatoumata B Sow, Frane Banovic
Intradermal injection of anti-immunoglobulin E (IgE) antibodies in dogs grossly and histologically resemble naturally occurring atopic dermatitis (AD). However, the activated inflammatory and pruritic pathways have not been characterized. The objectives of this study were to characterize the inflammatory transcriptome of experimental acute canine IgE-induced lesions and to determine how these correlate to the transcriptome of naturally occurring human and canine acute atopic dermatitis. Biopsies were collected at 6 and 24 h after intradermal injections of anticanine-IgE antibodies to eight healthy male castrated Beagles; healthy and saline-injected skin served as controls...
March 1, 2024: Veterinary Sciences
https://read.qxmd.com/read/38534999/a-comparison-of-68-ga-psma-pet-ct-based-split-renal-function-with-99m-tc-mag3-renography-in-patients-with-metastatic-castration-resistant-prostate-carcinoma-treated-with-177-lu-psma
#5
JOURNAL ARTICLE
Lerato Gabela, Thokozani Mkhize, Bawinile Hadebe, Lerwine Harry, Thembelihle Nxasana, Nontobeko Ndlovu, Venesen Pillay, Sphelele Masikane, Maryam Patel, Nozipho Elizabeth Nyakale, Mariza Vorster
BACKGROUND: Physiological PSMA expression in the cells of the proximal renal tubules and consecutive radiopharmaceutical binding and retention could potentially lead to radioligand-therapy-induced nephrotoxicity. Thus, patients with metastatic castration-resistant prostate cancer undergo 99m Tc-Mercaptoacetyltriglycine (MAG3) renal scintigraphy to assess kidney function and to exclude renal obstruction as part of their workup for PSMA-targeted radioligand therapy (RLT). 99m Tc-MAG-3 renal scintigraphy often requires an additional visit to the nuclear medicine department and patients spend 30-90 min in the department, which is inconvenient and takes up camera time...
March 8, 2024: Diagnostics
https://read.qxmd.com/read/38534939/-177-lu-psma-617-in-metastatic-castration-resistant-prostate-cancer-a-review-of-the-evidence-and-implications-for-canadian-clinical-practice
#6
REVIEW
Kim N Chi, Steven M Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J Hotte, David T Laidley, Fred Saad
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177 Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177 Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice...
March 7, 2024: Current Oncology
https://read.qxmd.com/read/38532425/symptoms-and-quality-of-life-among-men-starting-treatment-for-metastatic-castration-resistant-prostate-cancer-a-prospective-multicenter-study
#7
MULTICENTER STUDY
Ulrika Rönningås, Maja Holm, Per Fransson, Lars Beckman, Agneta Wennman-Larsen
BACKGROUND: Men with metastatic castration-resistant prostate cancer (mCRPC) have an incurable disease. Along with prolonging life, symptom management is one of the main goals with treatment. This is also important from a palliative care perspective where the life prolonging outcomes should be balanced with quality of life (QoL) in this late phase. It is also essential in symptom management to view different dimensions of symptoms, for example how severe or distressing symptoms are, to support best QoL...
March 27, 2024: BMC Palliative Care
https://read.qxmd.com/read/38532371/minimally-invasive-cytoreductive-radical-prostatectomy-exploring-the-safety-and-feasibility-of-a-single-port-or-multi-port-robotic-platform
#8
JOURNAL ARTICLE
Daniel J Lama, Kyle Thomas, Simone L Vernez, Oluwatimilehin Okunowo, Clayton S Lau, Bertram E Yuh
BACKGROUND: Consolidative resection or cytoreductive radical prostatectomy (CRP) may benefit men with non-organ confined prostate cancer. We report the safety, feasibility, and outcomes of robot-assisted laparoscopic CRP using a single-port (SP) or multi-port (MP) platform. METHODS: We reviewed consecutive men with clinical node positive or metastatic castrate-sensitive prostate cancer who underwent IRB-approved CRP and extended pelvic lymph node dissection using the da Vinci SP or MP Surgical Systems (Intuitive Surgical, Sunnyvale, CA) from 2015-2022...
March 26, 2024: BMC Urology
https://read.qxmd.com/read/38532114/sc912-inhibits-ar-v7-activity-in-castration-resistant-prostate-cancer-by-targeting-the-androgen-receptor-n-terminal-domain
#9
JOURNAL ARTICLE
Qianhui Yi, Xiaojun Han, Henry G Yu, Huei-Yu Chen, Dinghong Qiu, Jie Su, Rongtuan Lin, Gerald Batist, Jian Hui Wu
Androgen deprivation therapies (ADT) are the mainstay treatments for castration-resistant prostate cancer (CRPC). ADT suppresses the androgen receptor (AR) signaling by blocking androgen biosynthesis or inhibiting AR with antiandrogens that target AR's ligand-binding domain (LBD). However, the ADT's effect is short-lived, as the AR signaling inevitably arises again, which is frequently coupled with AR-V7 overexpression. AR-V7 is a truncated form of AR that lacks the LBD, thus being constitutively active in the absence of androgens and irresponsive to AR-LBD-targeting inhibitors...
March 26, 2024: Oncogene
https://read.qxmd.com/read/38531859/nuclear-receptor-nurr1-functions-to-promote-stemness-and-epithelial-mesenchymal-transition-in-prostate-cancer-via-its-targeting-of-wnt-%C3%AE-catenin-signaling-pathway
#10
JOURNAL ARTICLE
Xingxing Zhang, Haolong Li, Yuliang Wang, Hui Zhao, Zhu Wang, Franky Leung Chan
Dysregulated activation of Wnt/β-catenin signaling pathway is a frequent or common event during advanced progression of multiple cancers. With this signaling activation, it enhances their tumorigenic growth and facilitates metastasis and therapy resistance. Advances show that this signaling pathway can play dual regulatory roles in the control of cellular processes epithelial-mesenchymal transition (EMT) and cancer stemness in cancer progression. Aberrant activation of Wnt/β-catenin signaling pathway is shown to be common in prostate cancer and also castration-resistant prostate cancer (CRPC)...
March 26, 2024: Cell Death & Disease
https://read.qxmd.com/read/38531238/prevalence-and-factors-associated-with-leishmania-spp-and-toxoplasma-gondii-infections-in-apparently-healthy-horses-in-eastern-spain
#11
JOURNAL ARTICLE
Samuele Pala, Lola Martínez-Sáez, Lola Llobat, Pablo Jesús Marín-García
Leishmaniasis and toxoplasmosis are two of the most common parasitic zoonoses. Leishmaniasis is endemic to 98 countries around the world, whereas toxoplasmosis is widely distributed throughout the world, causing significant health expenditure. Horses can play a relevant role in the transmission of the disease, being a silent reservoir, as clinical signs are not common. Serum samples from 166 horses living in eastern Spain (Mediterranean basin) were analysed to determine the presence of antibodies against Leishmania spp...
March 21, 2024: Research in Veterinary Science
https://read.qxmd.com/read/38530321/androgenic-steroids-induce-pathologic-scarring-in-a-preclinical-porcine-model-via-dysfunctional-extracellular-matrix-deposition
#12
JOURNAL ARTICLE
Erik Reiche, Patrick R Keller, Vance Soares, Calvin R Schuster, Siti Rahmayanti, Jessica Mroueh, Vanessa Mroueh, Marie Billaud, Sophia Hu, Hunter Hoover-Watson, Christine G Lian, Yu Tan, Joshua C Doloff, Annie E Newell-Fugate, Devin Coon
Hypertrophic scarring is a major source of morbidity. Sex hormones are not classically considered modulators of scarring. However, based on increased frequency of hypertrophic scarring in patients on testosterone, we hypothesized that androgenic steroids induce abnormal scarring and developed a preclinical porcine model to explore these effects. Mini-swine underwent castration, received no testosterone (noT) or biweekly testosterone therapy (+T), and underwent excisional wounding. To create a delayed wound healing model, a subset of wounds were re-excised at 2 weeks...
March 31, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/38530086/combined-therapy-targeting-ar-and-ezh2-curbs-castration-resistant-prostate-cancer-enhancing-anti-tumor-t-cell-response
#13
JOURNAL ARTICLE
Irene Fischetti, Laura Botti, Roberta Sulsenti, Valeria Cancila, Claudia Enriquez, Renata Ferri, Marco Bregni, Filippo Crivelli, Claudio Tripodo, Mario P Colombo, Elena Jachetti
Aim: Castration-resistant prostate cancer (CRPC) eventually becomes resistant to androgen receptor pathway inhibitors like enzalutamide. Immunotherapy also fails in CRPC. We propose a new approach to simultaneously revert enzalutamide resistance and rewire anti-tumor immunity. Methods: We investigated in vitro and in subcutaneous and spontaneous mouse models the effects of combining enzalutamide and GSK-126, a drug inhibiting the epigenetic modulator EZH2. Results: Enzalutamide and GSK-126 synergized to reduce CRPC growth, also restraining tumor neuroendocrine differentiation...
March 26, 2024: Epigenomics
https://read.qxmd.com/read/38529181/metagenomic-sequencing-identified-microbial-species-in-the-rumen-and-cecum-microbiome-responsible-for-niacin-treatment-and-related-to-intramuscular-fat-content-in-finishing-cattle
#14
JOURNAL ARTICLE
Zhuqing Yang, Xiao Chen, Mingjin Yu, Ruixue Jing, Linbin Bao, Xianghui Zhao, Ke Pan, Bihui Chao, Mingren Qu
INTRODUCTION: Niacin is one of the essential vitamins for mammals. It plays important roles in maintaining rumen microecological homeostasis. Our previous study indicated that dietary niacin significantly elevated intramuscular fat content (IMF) in castrated finishing steers. Whether niacin affects fat deposition by regulating the microbial composition and functional capacities of gastrointestinal microbiome has been unknown yet. METHODS: In this study, 16 castrated Xiangzhong Black cattle were randomly assigned into either control group fed with a basal concentrate diet ( n  = 8) or niacin group fed with a basal concentrate diet added 1000 mg/kg niacin ( n  = 8)...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38528654/cd44-and-cd133-protein-expression-might-serve-as-a-prognostic-factor-for-early-occurrence-castration-resistant-prostate-cancer
#15
JOURNAL ARTICLE
Yayi Dwina, Litta Septina Mahmelia Zaid, Meilania Saraswati, Lisnawati Rachmadi, Aria Kekalih, Nur Rahadiani, Melva Louisa, Hasrayati Agustina, Chaidir Arif Mochtar, Agus Rizal Ardy Hariandy Hamid
BACKGROUND: The occurrence of castration-resistant prostate cancer (CRPC) varies in patients with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The rate of occurrence of CRPC may be related to the presence of prostate cancer stem cells (CSC). Thus, this study aims to evaluate the presence of CSC markers (CD44 and CD133) in histopathology tissue at the time of diagnosis and their correlation with the occurrence of CRPC in patients with advanced PCa within 2 years of ADT...
March 25, 2024: Prostate
https://read.qxmd.com/read/38528611/effects-of-alendronate-on-cartilage-lesions-and-micro-architecture-deterioration-of-subchondral-bone-in-patellofemoral-osteoarthritic-ovariectomized-rats-with-patella-baja
#16
JOURNAL ARTICLE
Mingjian Bei, Zhiyuan Zheng, Yaping Xiao, Ning Liu, Xuehui Cao, Faming Tian, Liu Zhang, Xinbao Wu
BACKGROUND: Patellofemoral osteoarthritis (PFJOA) is a subtype of knee OA, which is one of the main causes of anterior knee pain. The current study found an increased prevalence of OA in postmenopausal women, called postmenopausal OA. Therefore, we designed the ovariectomized rat model of patella baja-induced PFJOA. Alendronate (ALN) inhibits osteoclast-mediated bone loss, and has been reported the favorable result of a potential intervention option of OA treatment. However, the potential effects of ALN treatment on PFJOA in the ovariectomized rat model are unknown and need further investigation prior to exploration in the clinical research setting...
March 25, 2024: Journal of Orthopaedic Surgery and Research
https://read.qxmd.com/read/38528115/clinically-observed-foxa1-mutations-upregulate-sema3c-through-transcriptional-derepression-in-prostate-cancer
#17
JOURNAL ARTICLE
Kevin J Tam, Liangliang Liu, Michael Hsing, Kush Dalal, Daksh Thaper, Brian McConeghy, Parvin Yenki, Satyam Bhasin, James W Peacock, Yuzhuo Wang, Artem Cherkasov, Paul S Rennie, Martin E Gleave, Christopher J Ong
FOXA1 is a pioneer transcription factor that is frequently mutated in prostate, breast, bladder, and salivary gland malignancies. Indeed, metastatic castration-resistant prostate cancer (mCRPC) commonly harbour FOXA1 mutations with a prevalence of 35%. However, despite the frequent recurrence of FOXA1 mutations in prostate cancer, the mechanisms by which FOXA1 variants drive its oncogenic effects are still unclear. Semaphorin 3C (SEMA3C) is a secreted autocrine growth factor that drives growth and treatment resistance of prostate and other cancers and is known to be regulated by both AR and FOXA1...
March 25, 2024: Scientific Reports
https://read.qxmd.com/read/38527740/-chinese-expert-consensus-on-the-follow-up-management-of-patients-with-prostate-cancer-receiving-medical-castration-therapy%C3%AF-2024-edition%C3%AF
#18
JOURNAL ARTICLE
(no author information available yet)
With the advancement of prostate cancer (PCa) diagnosis and treatment technology, the 5-year survival rate has remarkably increased, and PCa has entered the era of chronic disease management. Medical castration therapy remains the cornerstone treatment option for PCa patients, and run throughout the various stages of patient treatment. The disease progression, treatment-related adverse reactions and related complications of PCa patients after medical castration have become a major problem in the long-term management of PCa patients, affecting the survival and quality of life of patients...
March 22, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38527252/accelerating-cellular-uptake-with-unnatural-amino-acid-for-inhibiting-immunosuppressive-cancer-cells
#19
JOURNAL ARTICLE
Meihui Yi, Gabriel Ashton-Rickardt, Weiyi Tan, Zhiyu Liu, Hongjian He, Jer-Tsong Hsieh, Bing Xu
Targeting immunosuppressive metastatic cancer cells is a key challenge in therapy. We recently have shown that a rigid-rod aromatic, pBP-NBD, that responds to enzymes and kill immunosuppressive metastatic osteosarcoma (mOS) and castration resistant prostate cancer (CRPC) cells in mimetic bone microenvironment. However, pBP-NBD demonstrated moderate efficacy against CRPC cells. To enhance activity, we incorporated the unnatural amino acid L- or D-4,4'-biphenylalanine (L- or D-BiP) into pBP-NBD, drastically increasing cellular uptake and CRPC inhibition...
March 25, 2024: Chemistry: a European Journal
https://read.qxmd.com/read/38527096/real-world-evaluation-of-primary-versus-secondary-prevention-of-skeletal-related-events-in-metastatic-castration-resistant-prostate-cancer
#20
JOURNAL ARTICLE
William J Phillips, Fred Saad, Jennifer Leigh, Alborz Jooya, Colleen Webber, Scott Morgan, Robert MacRae, Jean-Marc Bourque, Peter Tanuseputro, Michael Ong
INTRODUCTION: Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone-targeting agents (BTAs) relative to first palliative bone radiotherapy in patients dying of mCRPC. METHODS: Provincial administrative databases from Ontario, Canada identified patients with prostate cancer (2007-2018, n = 98 646) who received continuous androgen deprivation therapy (n = 29 453), died of prostate cancer (2013-2018, n = 3864), and received life-prolonging therapy for mCRPC (n = 1850)...
March 25, 2024: Oncologist
keyword
keyword
21176
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.